SI4070787T1 - Farmacevtske formulacije - Google Patents

Farmacevtske formulacije

Info

Publication number
SI4070787T1
SI4070787T1 SI201631707T SI201631707T SI4070787T1 SI 4070787 T1 SI4070787 T1 SI 4070787T1 SI 201631707 T SI201631707 T SI 201631707T SI 201631707 T SI201631707 T SI 201631707T SI 4070787 T1 SI4070787 T1 SI 4070787T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
SI201631707T
Other languages
English (en)
Inventor
Joanna M. Koziara
Scott Mccallister
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4070787(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI4070787T1 publication Critical patent/SI4070787T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SI201631707T 2015-06-30 2016-06-29 Farmacevtske formulacije SI4070787T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01
EP22176524.1A EP4070787B1 (en) 2015-06-30 2016-06-29 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SI4070787T1 true SI4070787T1 (sl) 2023-07-31

Family

ID=56418608

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201630656T SI3316868T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije, ki vsebujejo tenofovir in emtricitabin
SI201631702T SI4070788T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije
SI201631707T SI4070787T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije
SI201631582T SI3607939T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije, ki obsegajo tenofovir in emtricitabin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201630656T SI3316868T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije, ki vsebujejo tenofovir in emtricitabin
SI201631702T SI4070788T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201631582T SI3607939T1 (sl) 2015-06-30 2016-06-29 Farmacevtske formulacije, ki obsegajo tenofovir in emtricitabin

Country Status (26)

Country Link
US (2) US20170000807A1 (sl)
EP (5) EP4233846A3 (sl)
JP (3) JP6667556B2 (sl)
KR (2) KR102313668B1 (sl)
CN (1) CN107847450A (sl)
AU (3) AU2016287500B2 (sl)
BR (1) BR112017027843A2 (sl)
CA (1) CA2990210C (sl)
CL (1) CL2017003320A1 (sl)
CO (1) CO2017013293A2 (sl)
CU (1) CU20170168A7 (sl)
DO (1) DOP2017000306A (sl)
EA (1) EA201792592A1 (sl)
EC (1) ECSP17084331A (sl)
ES (4) ES2786549T3 (sl)
HK (1) HK1248547A1 (sl)
IL (1) IL256364A (sl)
MA (1) MA50541A (sl)
MX (1) MX2017016806A (sl)
PE (1) PE20180411A1 (sl)
PH (1) PH12017502431A1 (sl)
PL (4) PL4070788T3 (sl)
PT (4) PT4070788T (sl)
SI (4) SI3316868T1 (sl)
SV (1) SV2017005601A (sl)
WO (1) WO2017004244A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3608325T1 (sl) 2012-12-21 2022-09-30 Gilead Sciences, Inc. Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESSES FOR THE PREPARATION OF AG-10, ITS INTERMEDIARIES AND CORRESPONDING SALTS
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
CA3054822A1 (en) * 2017-03-20 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv post-exposure prophylaxis
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
CA3082191C (en) 2017-12-07 2021-09-21 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP3836920A4 (en) * 2018-08-17 2022-04-13 Eidos Therapeutics, Inc. AG10 FORMULATIONS
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100749160B1 (ko) 2000-07-21 2007-08-14 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물의 제조방법
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2512319A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
BRPI1008664A2 (pt) 2009-02-06 2016-03-08 Gilead Sciences Inc comprimidos para a terapia de combinação
HRP20161696T4 (hr) 2011-08-16 2023-10-13 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat
CA2863662A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
EA201690146A1 (ru) * 2013-08-14 2016-07-29 Ратиофарм Гмбх Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (sl) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
WO2017004244A1 (en) 2017-01-05
PT4070788T (pt) 2023-06-06
ES2945345T3 (es) 2023-06-30
AU2016287500A1 (en) 2018-01-18
ES2945896T3 (es) 2023-07-10
JP2020079304A (ja) 2020-05-28
ECSP17084331A (es) 2018-01-31
JP2018519297A (ja) 2018-07-19
PL4070787T3 (pl) 2023-07-24
PE20180411A1 (es) 2018-03-01
AU2019210558B2 (en) 2021-04-22
DOP2017000306A (es) 2018-01-15
KR102313668B1 (ko) 2021-10-19
EP4070788B1 (en) 2023-03-22
EA201792592A1 (ru) 2018-06-29
EP3316868A1 (en) 2018-05-09
PT4070787T (pt) 2023-05-22
US20170000807A1 (en) 2017-01-05
CN107847450A (zh) 2018-03-27
SI3316868T1 (sl) 2020-04-30
JP6978534B2 (ja) 2021-12-08
PL4070788T3 (pl) 2023-07-10
SI4070788T1 (sl) 2023-06-30
AU2019210558A1 (en) 2019-08-15
SI3607939T1 (sl) 2022-10-28
CL2017003320A1 (es) 2018-07-13
KR20200067937A (ko) 2020-06-12
PT3607939T (pt) 2022-09-12
CO2017013293A2 (es) 2018-05-31
PH12017502431A1 (en) 2018-07-02
PL3607939T3 (pl) 2022-11-07
EP4070787A1 (en) 2022-10-12
KR20180021134A (ko) 2018-02-28
EP3607939A1 (en) 2020-02-12
EP4233846A2 (en) 2023-08-30
EP4070788A1 (en) 2022-10-12
ES2786549T3 (es) 2020-10-13
AU2016287500B2 (en) 2019-05-02
SV2017005601A (es) 2018-05-04
CA2990210C (en) 2021-01-12
US20180177734A1 (en) 2018-06-28
EP3607939B1 (en) 2022-06-01
MX2017016806A (es) 2018-05-07
JP2021185188A (ja) 2021-12-09
EP4233846A3 (en) 2023-10-04
EP3316868B1 (en) 2020-02-19
CA2990210A1 (en) 2017-01-05
MA50541A (fr) 2021-04-07
AU2021202009B2 (en) 2023-04-13
ES2925246T3 (es) 2022-10-14
JP6667556B2 (ja) 2020-03-18
CU20170168A7 (es) 2018-07-05
AU2021202009A1 (en) 2021-04-29
BR112017027843A2 (pt) 2018-09-04
IL256364A (en) 2018-02-28
EP4070787B1 (en) 2023-03-01
PT3316868T (pt) 2020-04-21
HK1248547A1 (zh) 2018-10-19
PL3316868T3 (pl) 2020-10-19
KR102121329B1 (ko) 2020-06-17

Similar Documents

Publication Publication Date Title
IL246978A0 (en) New paracetamol formulations
SI4070788T1 (sl) Farmacevtske formulacije
HK1254343A1 (zh) 藥物製劑
ZA201903101B (en) Pharmaceutical formulations
IL262745A (en) Improved preparations containing drugs
GB201604124D0 (en) Pharmaceutical formulation
IL253177B (en) Pharmacy preparation
HK1245653A1 (zh) 藥物製劑
ZA201707094B (en) Pharmaceutical formulations
GB201521462D0 (en) Pharmaceutical composition
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
GB201515310D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
GB201609222D0 (en) Pharmaceutical formulation
GB201520862D0 (en) Pharmaceutical composition
GB201506755D0 (en) Novel pharmaceutical formulation
GB201511246D0 (en) Pharmaceutical formulation
IL271908A (en) Over-compressed pharmaceutical preparations
GB201417589D0 (en) Pharmaceutical Formulations
GB201610440D0 (en) Pharmaceutical formulations
PT3319596T (pt) Composições farmacêuticas
GB201521456D0 (en) Pharmaceutical composition
GB201506598D0 (en) Pharmaceutical compositions
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations